| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEB2 |
| Uniprot No | O15479 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-319aa |
| 氨基酸序列 | MPRGQKSKLRAREKRRKARDETRGLNVPQVTEAEEEEAPCCSSSVSGGAASSSPAAGIPQEPQRAPTTAAAAAAGVSSTKSKKGAKSHQGEKNASSSQASTSTKSPSEDPLTRKSGSLVQFLLYKYKIKKSVTKGEMLKIVGKRFREHFPEILKKASEGLSVVFGLELNKVNPNGHTYTFIDKVDLTDEESLLSSWDFPRRKLLMPLLGVIFLNGNSATEEEIWEFLNMLGVYDGEEHSVFGEPWKLITKDLVQEKYLEYKQVPSSDPPRFQFLWGPRAYAETSKMKVLEFLAKVNGTTPCAFPTHYEEALKDEEKAGV |
| 预测分子量 | 40.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAGEB2重组蛋白的3篇示例文献(注：部分信息为模拟示例，实际文献需根据具体研究补充)：
1. **文献名称**：*"Cloning and characterization of MAGEB2 as a cancer-testis antigen"*
**作者**：Chomez P., et al.
**摘要**：该研究克隆并鉴定了MAGEB2基因，证实其在睾丸和多种肿瘤组织中的特异性表达。通过重组蛋白技术在大肠杆菌中表达MAGEB2.并验证其抗原性，为癌症免疫治疗提供潜在靶点。
2. **文献名称**：*"Recombinant MAGEB2 protein purification and interaction analysis in melanoma cells"*
**作者**：Doyle J.M., et al.
**摘要**：研究利用His标签系统纯化重组MAGEB2蛋白，并发现其与黑色素瘤细胞中HSP70的相互作用，提示MAGEB2可能通过分子伴侣机制参与肿瘤细胞增殖调控。
3. **文献名称**：*"Functional study of MAGEB2 in regulating cell cycle via recombinant protein overexpression"*
**作者**：Sang L., et al.
**摘要**：通过体外过表达重组MAGEB2蛋白，发现其可结合细胞周期蛋白Cyclin D1并抑制G1/S期转化，揭示了MAGEB2在肿瘤发生中的潜在调控机制。
(注：以上文献为示例，实际引用需以真实发表的论文为准。)
**Background of MAGEB2 Recombinant Protein**
The **MAGEB2** (Melanoma Antigen Gene B2) protein belongs to the MAGE family of cancer-testis antigens (CTAs), which are predominantly expressed in germ cells and various cancers but remain silent in most healthy somatic tissues. Discovered in the 1990s, MAGE genes gained attention due to their tumor-specific expression, making them potential targets for cancer immunotherapy. MAGEB2. located on the X chromosome, is categorized under type I MAGE proteins, which share a conserved MAGE homology domain involved in protein-protein interactions and regulatory functions.
Biologically, MAGEB2 is implicated in transcriptional regulation, cell cycle control, and apoptosis, though its exact mechanisms remain under investigation. Its overexpression in cancers, such as melanoma, lung, and breast carcinomas, correlates with tumor progression, metastasis, and poor prognosis. This restricted expression profile positions MAGEB2 as a promising biomarker and therapeutic target for cancer-specific treatments.
**Recombinant MAGEB2 protein** is engineered using biotechnological methods, often through heterologous expression systems like *E. coli* or mammalian cells. The recombinant form retains the immunogenic epitopes of the native protein, enabling its use in antibody production, T-cell activation studies, and vaccine development. Researchers utilize it to investigate MAGEB2’s role in oncogenesis, immune evasion, and to screen potential inhibitors.
Despite its potential, challenges persist, including understanding its physiological role in normal tissues and addressing immune tolerance mechanisms that limit therapeutic efficacy. Ongoing studies aim to harness MAGEB2’s cancer-specific expression for precision oncology, particularly in adoptive T-cell therapies and peptide-based vaccines. Its development underscores the growing focus on CTAs in advancing personalized cancer immunotherapies.
×
